Device-Activated Drugs, An Old Dog With Some New Tricks
Executive Summary
As technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. Medtech Insight spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.